A Phase 2 interventional study of Motavizumab, palivizumab and Palivizumab, motavizumab in Respiratory Syncytial Virus Infections, Chronic Lung Disease and <= 24 Months of Age or and Premature With Gestational Age <=35 Weeks and <=6 Months of Age, sponsored by MedImmune LLC. Completed at 19 sites in 3 countries. Open to participants aged Up to 24 Months. Per ClinicalTrials.gov, last updated 2012-12-11.
Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca — none open to participants now, none under way, none of them phase 3. Respiratory Syncytial Virus Infections · AstraZeneca.
Among the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca, this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2006, is one of 3 in phase 2, and was the 5th registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →None of the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca is open now. The open studies under Respiratory Syncytial Virus Infections, anywhere →
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: Up to 24 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 4
First in 2003; this study’s year is marked. 2 started in 2006.
This study's enrollment of 260 is above the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 239 across the 12 interventional studies, 233 across the 2 observational. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under MedImmune LLC, one of the names counted as AstraZeneca. Under that name alone:
MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.
Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, randomized, double-blind study in which motavizumab (MEDI-524) and palivizumab were administered sequentially to high-risk children during the same respiratory syncytial virus (RSV) season. A control group was administered only motavizumab.
This is a Phase 2, randomized, double-blind study in which motavizumab and palivizumab were administered sequentially to high-risk children during the same RSV season. It was anticipated that approximately 240 children (80 in each group) would be enrolled from the southern hemisphere during the upcoming RSV season (2006). Children were randomized into one of three regimens in a 1:1:1 ratio; the first group received 2 doses of motavizumab followed by 3 doses of palivizumab; the second group received 2 doses of palivizumab followed by 3 doses of motavizumab; and the third group received 5 doses of motavizumab. Motavizumab or palivizumab was administered at 15 mg/kg by IM injection every 30 days, for a total of 5 injections.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month)
Biological: Motavizumab, palivizumab
2 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)
Biological: Palivizumab, motavizumab
5 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)
Biological: Motavizumab
Drug pages: Motavizumab · Palivizumab
Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.
Drug pages: Palivizumab · Motavizumab
Palivizumab was provided in sterile vials containing 100 mg of palivizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine, and 1.6 mM glycine.
Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.
Number of Subjects Reporting Serious Adverse Events (SAEs)
Time frame: Day 0 - Day 150
Number of Subjects Reporting Adverse Events (AEs)
Time frame: Day 0 - Day 150
Number of Subjects With Changes in Laboratory Chemistry Values Reported as AEs.
Serum chemistry samples were collected at Day 0, Day 60, and Day 150. Values representing changes in severity according to the AE grading table were recorded as AEs.
Time frame: Day 0 - Day 150
The Serum Concentrations of Motavizumab at Day 0
Time frame: Day 0
The Trough Serum Concentrations of Motavizumab at Day 60
Time frame: Day 60
The Trough Serum Concentrations of Motavizumab at Day 150
Time frame: Day 150
The Trough Serum Concentrations of Motavizumab 120-150 Days Post Final Dose
Time frame: 120-150 days post final dose
The Serum Concentrations of Palivizumab at Day 0
Time frame: Day 0
The Trough Serum Concentrations of Palivizumab at Day 60
Time frame: Day 60
The Trough Serum Concentrations of Palivizumab at Day 150
Time frame: Day 150
The Trough Serum Concentrations of Palivizumab at 120-150 Days Post Final Dose
Time frame: 120-150 days post final dose
The Immunogenicity of Motavizumab at Day 0
Number of subjects with detected anti-motavivumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.
Time frame: Day 0
The Immunogenicity of Motavizumab at Day 60
Number of subjects with detected anti-motavivumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.
Time frame: Day 60
The Immunogenicity of Motavizumab at Day 150
Number of subjects with detected anti-motavivumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.
Time frame: Day 150
The Immunogenicity of Motavizumab at 120 to 150 Days Post Final Dose
Number of subjects with detected anti-motavivumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.
Time frame: 120 - 150 days post final dose
The Immunogenicity of Motavizumab at Any Time
Number of subjects with detected anti-motavivumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.
Time frame: At any time
The Immunogenicity of Palivizumab at Day 0
Number of subjects with detected anti-palivizumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.
Time frame: Day 0
The Immunogenicity of Palivizumab at Day 60
Number of subjects with detected anti-palivizumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.
Time frame: Day 60
The Immunogenicity of Palivizumab at Day 150
Number of subjects with detected anti-palivizumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.
Time frame: Day 150
The Immunogenicity of Palivizumab at 120 to 150 Days Post Final Dose
Number of subjects with detected anti-palivizumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.
Time frame: 120 - 150 days post final pose
The Immunogenicity of Palivizumab at Any Time
Number of subjects with detected anti-palivizumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.
Time frame: At any time
It was anticipated that approximately 240 children (80 in each group) would be enrolled from the southern hemisphere during the upcoming RSV season (2006).
| Milestone | Motavizumab (MEDI-524) Followed by Palivizumab | Palivizumab Followed by Motavizumab (MEDI-524) | Motavizumab (MEDI-524) Control |
|---|---|---|---|
| Started | 83 | 84 | 93 |
| Completed | 77 | 77 | 87 |
| Not completed | 6 | 7 | 6 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Withdrawal of consent | 3 | 5 | 6 |
| Withdrew: Death | 2 | 0 | 0 |
| Withdrew: Other | 1 | 1 | 0 |
| participants | Motavizumab (MEDI-524) Followed by Palivizumab | Palivizumab Followed by Motavizumab (MEDI-524) | Motavizumab (MEDI-524) Control |
|---|---|---|---|
| Number of Subjects Reporting Serious Adverse Events (SAEs) | 19 | 7 | 11 |
| participants | Motavizumab (MEDI-524) Followed by Palivizumab | Palivizumab Followed by Motavizumab (MEDI-524) | Motavizumab (MEDI-524) Control |
|---|---|---|---|
| Number of Subjects Reporting Adverse Events (AEs) | 77 | 75 | 83 |
Serum chemistry samples were collected at Day 0, Day 60, and Day 150. Values representing changes in severity according to the AE grading table were recorded as AEs.
| participants | Motavizumab (MEDI-524) Followed by Palivizumab | Palivizumab Followed by Motavizumab (MEDI-524) | Motavizumab (MEDI-524) Control |
|---|---|---|---|
| Alanine aminotransferase increased | 1 | 1 | 5 |
| Hepatic enzyme increased | 1 | 0 | 0 |
| Liver function test abnormal | 0 | 0 | 1 |
| Blood urea increased | 1 | 1 | 3 |
| Aspartate aminotransferase increased | 2 | 3 | 2 |
| μg/mL | Motavizumab (MEDI-524) Followed by Palivizumab | Palivizumab Followed by Motavizumab (MEDI-524) | Motavizumab (MEDI-524) Control |
|---|---|---|---|
| The Serum Concentrations of Motavizumab at Day 0 | NA ± NA | NA ± NA | NA ± NA |
| μg/mL | Motavizumab (MEDI-524) Followed by Palivizumab | Palivizumab Followed by Motavizumab (MEDI-524) | Motavizumab (MEDI-524) Control |
|---|---|---|---|
| The Trough Serum Concentrations of Motavizumab at Day 60 | 74.74 ± 27.50 | 0.9417 ± 2.287 | 78.02 ± 28.98 |
| μg/mL | Motavizumab (MEDI-524) Followed by Palivizumab | Palivizumab Followed by Motavizumab (MEDI-524) | Motavizumab (MEDI-524) Control |
|---|---|---|---|
| The Trough Serum Concentrations of Motavizumab at Day 150 | 8.801 ± 5.682 | 93.05 ± 30.97 | 105.8 ± 37.49 |
| μg/mL | Motavizumab (MEDI-524) Followed by Palivizumab | Palivizumab Followed by Motavizumab (MEDI-524) | Motavizumab (MEDI-524) Control |
|---|---|---|---|
| The Trough Serum Concentrations of Motavizumab 120-150 Days Post Final Dose | 0.5078 ± 1.031 | 7.586 ± 5.152 | 10.01 ± 6.341 |
| μg/mL | Motavizumab (MEDI-524) Followed by Palivizumab | Palivizumab Followed by Motavizumab (MEDI-524) | Motavizumab (MEDI-524) Control |
|---|---|---|---|
| The Serum Concentrations of Palivizumab at Day 0 | NA ± NA | NA ± NA | NA ± NA |
| μg/mL | Motavizumab (MEDI-524) Followed by Palivizumab | Palivizumab Followed by Motavizumab (MEDI-524) | Motavizumab (MEDI-524) Control |
|---|---|---|---|
| The Trough Serum Concentrations of Palivizumab at Day 60 | 8.103 ± 6.907 | 87.37 ± 17.41 | 8.795 ± 6.578 |
| μg/mL | Motavizumab (MEDI-524) Followed by Palivizumab | Palivizumab Followed by Motavizumab (MEDI-524) | Motavizumab (MEDI-524) Control |
|---|---|---|---|
| The Trough Serum Concentrations of Palivizumab at Day 150 | 107.4 ± 30.21 | 22.89 ± 5.631 | 12.99 ± 7.472 |
| μg/mL | Motavizumab (MEDI-524) Followed by Palivizumab | Palivizumab Followed by Motavizumab (MEDI-524) | Motavizumab (MEDI-524) Control |
|---|---|---|---|
| The Trough Serum Concentrations of Palivizumab at 120-150 Days Post Final Dose | 7.667 ± 7.719 | NA ± NA | NA ± NA |
Number of subjects with detected anti-motavivumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.
| participants with detected antibody | Motavizumab (MEDI-524) Followed by Palivizumab | Palivizumab Followed by Motavizumab (MEDI-524) | Motavizumab (MEDI-524) Control |
|---|---|---|---|
| The Immunogenicity of Motavizumab at Day 0 | 0 | 1 | 0 |
Number of subjects with detected anti-motavivumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.
| participants with detected antibody | Motavizumab (MEDI-524) Followed by Palivizumab | Palivizumab Followed by Motavizumab (MEDI-524) | Motavizumab (MEDI-524) Control |
|---|---|---|---|
| The Immunogenicity of Motavizumab at Day 60 | 0 | 0 | 0 |
Number of subjects with detected anti-motavivumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.
| participants with detected antibody | Motavizumab (MEDI-524) Followed by Palivizumab | Palivizumab Followed by Motavizumab (MEDI-524) | Motavizumab (MEDI-524) Control |
|---|---|---|---|
| The Immunogenicity of Motavizumab at Day 150 | 1 | 1 | 0 |
Number of subjects with detected anti-motavivumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.
| participants with detected antibody | Motavizumab (MEDI-524) Followed by Palivizumab | Palivizumab Followed by Motavizumab (MEDI-524) | Motavizumab (MEDI-524) Control |
|---|---|---|---|
| The Immunogenicity of Motavizumab at 120 to 150 Days Post Final Dose | 3 | 1 | 0 |
Number of subjects with detected anti-motavivumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.
| participants with detected antibody | Motavizumab (MEDI-524) Followed by Palivizumab | Palivizumab Followed by Motavizumab (MEDI-524) | Motavizumab (MEDI-524) Control |
|---|---|---|---|
| The Immunogenicity of Motavizumab at Any Time | 4 | 2 | 0 |
Number of subjects with detected anti-palivizumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.
| participants with detected antibody | Motavizumab (MEDI-524) Followed by Palivizumab | Palivizumab Followed by Motavizumab (MEDI-524) | Motavizumab (MEDI-524) Control |
|---|---|---|---|
| The Immunogenicity of Palivizumab at Day 0 | 0 | 0 | 0 |
Number of subjects with detected anti-palivizumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.
| participants with detected antibody | Motavizumab (MEDI-524) Followed by Palivizumab | Palivizumab Followed by Motavizumab (MEDI-524) | Motavizumab (MEDI-524) Control |
|---|---|---|---|
| The Immunogenicity of Palivizumab at Day 60 | 1 | 1 | 1 |
Number of subjects with detected anti-palivizumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.
| participants with detected antibody | Motavizumab (MEDI-524) Followed by Palivizumab | Palivizumab Followed by Motavizumab (MEDI-524) | Motavizumab (MEDI-524) Control |
|---|---|---|---|
| The Immunogenicity of Palivizumab at Day 150 | 2 | 1 | 0 |
Number of subjects with detected anti-palivizumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.
| participants with detected antibody | Motavizumab (MEDI-524) Followed by Palivizumab | Palivizumab Followed by Motavizumab (MEDI-524) | Motavizumab (MEDI-524) Control |
|---|---|---|---|
| The Immunogenicity of Palivizumab at 120 to 150 Days Post Final Dose | 3 | 0 | 0 |
Number of subjects with detected anti-palivizumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.
| participants with detected antibody | Motavizumab (MEDI-524) Followed by Palivizumab | Palivizumab Followed by Motavizumab (MEDI-524) | Motavizumab (MEDI-524) Control |
|---|---|---|---|
| The Immunogenicity of Palivizumab at Any Time | 4 | 2 | 1 |
Collected over Day 0 - Day 150. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Motavizumab (MEDI-524) Followed by Palivizumab | — | 19/83 (22.9%) | 75/83 (90.4%) |
| Palivizumab Followed by Motavizumab (MEDI-524) | — | 7/83 (8.4%) | 74/83 (89.2%) |
| Motavizumab (MEDI-524) Control | — | 11/93 (11.8%) | 83/93 (89.2%) |
| Event | Motavizumab (MEDI-524) Followed by Palivizumab | Palivizumab Followed by Motavizumab (MEDI-524) | Motavizumab (MEDI-524) Control |
|---|---|---|---|
| BRONCHIOLITISInfections and infestations | 6/83 | 1/83 | 3/93 |
| PNEUMONIAInfections and infestations | 3/83 | 0/83 | 1/93 |
| INGUINAL HERNIAGastrointestinal disorders | 0/83 | 2/83 | 1/93 |
| Visual disturbanceEye disorders | 1/83 | 0/83 | 0/93 |
| GASTROOESOPHAGEAL REFLUX DISEASEGastrointestinal disorders | 1/83 | 0/83 | 0/93 |
| BRONCHITISInfections and infestations | 1/83 | 0/83 | 0/93 |
| BRONCHITIS VIRALInfections and infestations | 1/83 | 0/83 | 0/93 |
| CROUP INFECTIOUSInfections and infestations | 1/83 | 0/83 | 0/93 |
| GASTROENTERITISInfections and infestations | 1/83 | 0/83 | 0/93 |
| LOWER RESPIRATORY TRACT INFECTIONInfections and infestations | 0/83 | 1/83 | 0/93 |
| Event | Motavizumab (MEDI-524) Followed by Palivizumab | Palivizumab Followed by Motavizumab (MEDI-524) | Motavizumab (MEDI-524) Control |
|---|---|---|---|
| NASOPHARYNGITISInfections and infestations | 25/83 | 26/83 | 23/93 |
| BRONCHITISInfections and infestations | 14/83 | 20/83 | 19/93 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 17/83 | 15/83 | 18/93 |
| WHEEZINGRespiratory, thoracic and mediastinal disorders | 15/83 | 8/83 | 10/93 |
| CONJUNCTIVITISEye disorders | 6/83 | 11/83 | 16/93 |
| TEETHINGGastrointestinal disorders | 10/83 | 9/83 | 16/93 |
| RHINITISInfections and infestations | 10/83 | 14/83 | 8/93 |
| DIARRHOEAGastrointestinal disorders | 12/83 | 13/83 | 11/93 |
| IRRITABILITYGeneral disorders | 10/83 | 11/83 | 11/93 |
| DERMATITIS DIAPERSkin and subcutaneous tissue disorders | 5/83 | 10/83 | 10/93 |
| Age Continuous(months) | Motavizumab (MEDI-524) Followed by Palivizumab | Palivizumab Followed by Motavizumab (MEDI-524) | Motavizumab (MEDI-524) Control | Total |
|---|---|---|---|---|
| Mean | 3.68 ± 3.13 | 3.35 ± 2.25 | 3.92 ± 2.43 | 3.66 ± 2.62 |
| Sex: Female, Male(Participants) | Motavizumab (MEDI-524) Followed by Palivizumab | Palivizumab Followed by Motavizumab (MEDI-524) | Motavizumab (MEDI-524) Control | Total |
|---|---|---|---|---|
| Female | 32 | 41 | 45 | 118 |
| Male | 51 | 43 | 48 | 142 |
The record gives a start of Apr 2006, a primary completion of Feb 2007 and a completion of Feb 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2012, 5 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Motavizumab · Palivizumab
Respiratory Syncytial Virus Infections →